Literature DB >> 24592098

The metabolic effects of drugs used for the treatment of polycystic ovary syndrome.

Melia Karaköse1, Erman Cakal1, Kubilay Ertan2, Tuncay Delibaşı1.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. It is characterized by menstrual disorders, hyperandrogenism (clinical and/or biochemical) and ultrasonographic features. It is well known that PCOS has unfavourable effects on carbohydrate metabolism, the parameters of cardiovascular disease and lipid profile. Mode of treatment is mainly guided by the main complaint of the patient. A lot of medicines have been used for many years to treat these women. For that reason the recognition the effects of these drugs on the metabolic risk profile is important. The aim of this review was to evaluate the effects of these drugs on metabolic parameters in women with PCOS.

Entities:  

Keywords:  Polycystic ovary syndrome; drug effects; metabolic parameter; treatment

Year:  2013        PMID： 24592098      PMCID： PMC3928416          DOI： 10.5152/jtgga.2013.57701

Source DB:  PubMed          Journal:  J Turk Ger Gynecol Assoc        ISSN： 1309-0380


  48 in total

1.  Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance.

Authors:  Andrea D Coviello; Richard S Legro; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2005-10-25       Impact factor: 5.958

2.  A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.

Authors:  E Diamanti-Kandarakis; C R Kouli; A T Bergiele; F A Filandra; T C Tsianateli; G G Spina; E D Zapanti; M I Bartzis
Journal:  J Clin Endocrinol Metab       Date:  1999-11       Impact factor: 5.958

3.  Alteration of cardiovascular risk parameters in women with polycystic ovary syndrome who were prescribed to ethinyl estradiol-cyproterone acetate.

Authors:  Funda Gode; Cigdem Karagoz; Cemal Posaci; Bahadir Saatli; Didem Uysal; Mustafa Secil; Bahri Akdeniz
Journal:  Arch Gynecol Obstet       Date:  2010-12-08       Impact factor: 2.344

4.  Relationship of adolescent polycystic ovary syndrome to parental metabolic syndrome.

Authors:  Natasha I Leibel; Elizabeth E Baumann; Masha Kocherginsky; Robert L Rosenfield
Journal:  J Clin Endocrinol Metab       Date:  2006-01-31       Impact factor: 5.958

Review 5.  The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.

Authors:  Ricardo Azziz; Enrico Carmina; Didier Dewailly; Evanthia Diamanti-Kandarakis; Héctor F Escobar-Morreale; Walter Futterweit; Onno E Janssen; Richard S Legro; Robert J Norman; Ann E Taylor; Selma F Witchel
Journal:  Fertil Steril       Date:  2008-10-23       Impact factor: 7.329

6.  Polycystic ovary syndrome is associated with tissue-specific differences in insulin resistance.

Authors:  Theodore P Ciaraldi; Vanita Aroda; Sunder Mudaliar; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-10-14       Impact factor: 5.958

7.  [Effect of 6-month treatment with oral antiandrogen alone and in combination with insulin sensitizers on body composition, hormonal and metabolic parameters in women with polycystic ovary syndrome (PCOS) in order to determine therapeutic strategy].

Authors:  M Orbetsova; Z Kamenov; G Kolarov; S Zakharieva; V Khristov; I Atanasova; R Shigarminova; B Milcheva; G Genchev
Journal:  Akush Ginekol (Sofiia)       Date:  2006

Review 8.  Recent advances in the treatment of polycystic ovary syndrome.

Authors:  Bulent O Yildiz
Journal:  Expert Opin Investig Drugs       Date:  2004-10       Impact factor: 6.206

9.  Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.

Authors:  M Ashraf Ganie; M L Khurana; M Eunice; N Gupta; M Gulati; S N Dwivedi; A C Ammini
Journal:  J Clin Endocrinol Metab       Date:  2004-06       Impact factor: 5.958

10.  The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study.

Authors:  Francesco Orio; Stefano Palomba; Letizia Spinelli; Teresa Cascella; Libuse Tauchmanovà; Fulvio Zullo; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2004-08       Impact factor: 5.958
View more
  1 in total

1.  Correlation of endometrial glycodelin expression and pregnancy outcome in cases with polycystic ovary syndrome treated with clomiphene citrate plus metformin: a controlled study.

Authors:  Selda Uysal; Ahmet Zeki Isik; Serenat Eris; Seyran Yigit; Yakup Yalcin; Pelin Ozun Ozbay
Journal:  Obstet Gynecol Int       Date:  2015-02-28
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.